Although there is currently no data supporting the use of UBE2O as a prognostic marker or for predicting therapy response in solid tumors or hematological malignancies, the role of this enzyme suggests that it could potentially serve as a biomarker for therapy response in the future. Here, UBE2O is linked to hematologic disorder.